The foundation, which has provided support to Arcturus since 2017, boosted its commitment to the company to advance LUNAR-CF, Arcturus's first inhaled mRNA therapeutic targeting the lung. The medication is designed to deliver normal mRNA into lung cells and enable patients to produce healthy, functional CFTR (cystic fibrosis transmembrane conductance regulator) protein naturally, regardless of mutation, in their own lung cells. The funding will support an ongoing multiyear program aimed at creating mRNA therapies for people with cystic fibrosis, developing methods to deliver RNA components to cells in the lung, and filing an Investigational New Drug application for a therapeutic candidate.
"We are pleased with the progress we have made in our agreement with the CF Foundation, including preclinical proof of concept studies, demonstrating that LUNAR is able to deliver mRNA efficiently into lung epithelial cells in animals and is compatible with nebulization," said Arcturus Therapeutics president and CEO Joseph Payne. "We are delighted with the expanded financial support from the CF Foundation, and we believe that we are now sufficiently funded to advance the LUNAR-CF program into filing an IND application."